Maze Therapeutics, Inc.
MAZE
Positions held
Your positionsMAZE isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Maze Therapeutics operates in a competitive biotechnology sector with a strong focus on innovative therapies, which positions it well for future growth.
- The company's market cap is approximately $1.47 billion, indicating significant investor interest.
- Maze has a strong buy recommendation with a target mean price of $61.5.
- Maze Therapeutics faces challenges with a high debt-to-equity ratio of 13.335, which may impact financial stability.
- In the most recent quarter, Maze reported a revenue drop of 100% compared to the prior quarter, going from $20 million to $0.
- The company has consistently reported net losses, with a net income of -131.12 million for the year 2025.
Fundamentals
| Market cap | $1.44B | Enterprise value | $1.09B | Trailing P/E | — | Forward P/E | -8.03 |
| PEG | — | Price / book | 3.17 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 100.0% | Operating margin | -7.3% |
| Profit margin | 0.0% | ROE | -37.3% | ROA | -21.8% | Debt / equity | 0.13 |
| Current ratio | 18.31 | Free cash flow | -$63.63M | Analyst recommendation | strong_buy | Mean target | $61.50 |
| 52w high | $53.65 | 52w low | $21.95 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $20.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | -132.8% | — | — | — | — |
| Net income | -$44.7M | -$24.2M | -$34.6M | -$30.1M | -$33.7M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$48.0M | -$26.6M | -$38.1M | -$33.0M | -$36.5M | — |
- Revenue -100% vs prior quarter ($0 vs $20M).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $168M | $0.0M | $0.0M |
| Op margin | — | 34.4% | — | — |
| Net income | -$131M | $52.2M | -$100M | -$115M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$143M | $57.6M | -$98.6M | -$111M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
2026-10-05 · 3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight
2026-09-29 · Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?
2026-09-25 · Maze Therapeutics (MAZE) Shares Moved, So What Is Driving Attention Now?
2026-09-23 · Maze Therapeutics Shares Rise 2.9% After CIBC Initiates Coverage
2026-09-23 · Correction: Citigroup Initiates Maze Therapeutics at Buy With $50 Price Target
2026-09-23 · BTIG Initiates Maze Therapeutics at Buy With $50 Price Target
2026-09-22 · The Surprise That Sent Vertex — And Its Chief Rival — Soaring
2026-09-22 · Twin Moves: VRTX Rises On Kidney Disease Trial Results, MAZE Rallies Harder
2026-09-22 · Vertex’s Kidney Drug Success Sparks a 22% Surge for This Rival Biotech
2026-09-15 · SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
2026-09-11 · Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000
Price (daily)
Full chart · RSI · MACD · patterns